Teclistamab Monotherapy in Relapsed or Refractory Multiple Myeloma: A Real-World Focused Systematic Review and Meta-Analysis of Efficacy and Safety

Jerry Qi, Daniel Park, Pranati Shah, Mojtaba Akhtari

Open source

DOI
10.3390/hematolrep18040054
Published
2026-08-03
Container
Hematology Reports
Publisher
MDPI AG
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/hematolrep18040054,
  title = {Teclistamab Monotherapy in Relapsed or Refractory Multiple Myeloma: A Real-World Focused Systematic Review and Meta-Analysis of Efficacy and Safety},
  author = {Jerry Qi and Daniel Park and Pranati Shah and Mojtaba Akhtari},
  year = {2026},
  journal = {Hematology Reports},
  doi = {10.3390/hematolrep18040054},
  url = {https://doi.org/10.3390/hematolrep18040054}
}

RIS

TY  - JOUR
TI  - Teclistamab Monotherapy in Relapsed or Refractory Multiple Myeloma: A Real-World Focused Systematic Review and Meta-Analysis of Efficacy and Safety
AU  - Jerry Qi
AU  - Daniel Park
AU  - Pranati Shah
AU  - Mojtaba Akhtari
PY  - 2026
JO  - Hematology Reports
DO  - 10.3390/hematolrep18040054
UR  - https://doi.org/10.3390/hematolrep18040054
ER  - 

APA

Qi, J., Park, D., Shah, P., & Akhtari, M. (2026). Teclistamab Monotherapy in Relapsed or Refractory Multiple Myeloma: A Real-World Focused Systematic Review and Meta-Analysis of Efficacy and Safety. Hematology Reports. https://doi.org/10.3390/hematolrep18040054

Source records